Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure

Current Heart Failure Reports

Volumn 11, Issue 2, 2014, Pages 146-155

  Askevold, Erik Tandberg ^a   Gullestad, Lars ^a   Dahl, Christen P ^a   Yndestad, Arne ^a   Ueland, Thor ^a   Aukrust, Pål ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokine; Heart failure; Inflammation; Interleukin 6; Risk prediction; Sgp130; Therapy

Indexed keywords

BIOLOGICAL MARKER; CANAKINUMAB; EPIGALLOCATECHIN GALLATE; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 130 FC FUSION PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; METHOTREXATE; OXIPURINOL; PENTOXIFYLLINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; GLYCOPROTEIN; GLYCOPROTEIN 130, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; DRUG TARGETING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNE SYSTEM; IMMUNOADSORPTION; INFLAMMATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; BLOOD; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CYTOKINE RECEPTOR GP130; GLYCOPROTEINS; HEART FAILURE; HUMANS; INFLAMMATION; INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84903608069     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0185-9     Document Type: Review

References (108)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-41. (Pubitemid 20225044)
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the f oreseeable future. Circ Res. 2002;91(11):988-98. (Pubitemid 35416635)
3. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev. 2006;11(1):83-92. (Pubitemid 43986210)
4. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83(3):376-82. (Pubitemid 29066497)
5. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9. (Pubitemid 32373007)
6. Heymans S,Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(2):119-29.
7. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201-6. (Pubitemid 26117714)
8. Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010;122(17):1700-6.
9. Ky B, French B, Levy WC, Sweitzer NK, Fang JC,Wu AH, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5(2):183-90.
10. Braunwald E. Heart Failure. JACC Heart Fail. 2013;1(1):1-20.
11. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012;122(1):23-35.
12. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58(2):88-111.
13. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res. 2011;108(9):1122-32.
14. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circulation research. 2011;108(9):1133-45.
15. Rogler G, Rosano G. The heart and the gut. Eur Heart J. 2013 Jul 17 [Epub ahead of print].
16. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94(12):1543-53. (Pubitemid 38856961)
17. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101(17):2103-9. (Pubitemid 30233176)
18. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res. 2009;81(3):474-81.
19. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159-73.
20. Jiang B, Liao R. The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res. 2010;3(4):410-6.
21. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99(25):3224-6. (Pubitemid 29293430)
22. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602. (Pubitemid 38451714)
23. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40. (Pubitemid 36793081)
24. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol. 2005;95(11A):17C- 23C. discussion 38C-40C.
25. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083-8. (Pubitemid 32200181)
26. Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112(22):3408-14. (Pubitemid 43739555)
27. Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J. 2006;151(1):62-8. (Pubitemid 41815332)
28. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101(4):385-91. (Pubitemid 30067394)
29. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. (Pubitemid 32095406)
30. Hare JM, Mangal B, Brown J, Fisher Jr C, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301-9. (Pubitemid 351783365)
31. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. (Pubitemid 350190755)
32. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9.
33. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371(9608):228-36.
34. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332-9.
35. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394-400.
36. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, et al. Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the DHART Pilot Study). Am J Cardiol. 2013 Oct 4 [Epub ahead of print].
37. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605.
38. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6(2):95-103. (Pubitemid 32328172)
39. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al.WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172(4):2225-31. (Pubitemid 38182370)
40. Derouet D, Rousseau F, Alfonsi F, Froger J, Hermann J, Barbier F, et al. Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA. 2004;101(14):4827-32. (Pubitemid 38469162)
41. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-54.
42. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183(4):1399-406. (Pubitemid 26134283)
43. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-36. (Pubitemid 44835496)
44. Baumann H, Wang Y, Morella KK, Lai CF, Dams H, Hilton DJ, et al. Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J Immunol. 1996;157(1):284-90. (Pubitemid 26190559)
45. NarazakiM, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82(4):1120-6. (Pubitemid 23253984)
46. Jostock T,Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160-7. (Pubitemid 32052260)
47. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008;153 Suppl 1:S414-27. (Pubitemid 351341017)
48. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol. 2007;102(5):393-411. (Pubitemid 47278812)
49. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257(5068):387-9.
50. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, et al. Interleukin-6 causesmyocardial failure and skeletal muscle atrophy in rats. Circulation. 2005;111(8):996-1005. (Pubitemid 40354517)
51. Villegas S, Villarreal FJ, Dillmann WH. Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol. 2000;95(1):47-54. (Pubitemid 30150727)
52. Patten M, Kramer E, Bunemann J, Wenck C, Thoenes M, Wieland T, et al. Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo. Pflugers Arch. 2001;442(6): 920-7. (Pubitemid 32900453)
53. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19(5):237-41. (Pubitemid 39335083)
54. Tsutamoto T,Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;38(5):1485-90. (Pubitemid 33033030)
55. Gwechenberger M, Pacher R, Berger R, Zorn G, Moser P, Stanek B, et al. Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J Heart Lung Transplant. 2005;24(12):2190-5. (Pubitemid 41814745)
56. Eiken HG, Oie E, Damas JK, Yndestad A, Bjerkeli V, Aass H, et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest. 2001;31(5):389-97. (Pubitemid 32476958)
57. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 2002;106(12):1442-6.
58. Plenz G, Song ZF, Tjan TD, Koenig C, Baba HA, Erren M, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001;3(4):415-21. (Pubitemid 32776868)
59. Yan AT, Yan RT, Cushman M, Redheuil A, Tracy RP, Arnett DK, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31(7):875 -82.
60. Harhay MO, Tracy RP, Bagiella E, Barr RG, Pinder D, Hundley WG, et al. Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study. Int J Cardiol. 2013;168(4):3818-24.
61. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross Jr J, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97(2):189-98. (Pubitemid 29194270)
62. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenationinduced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation. 2001;104(9):979-81. (Pubitemid 32803871)
63. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, Chai GX, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 2003;100(22):12929-34. (Pubitemid 37340002)
64. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation. 1998;98(4):346-52. (Pubitemid 28348057)
65. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004;95(2):187-95. (Pubitemid 38988685)
66. Freed DH, Moon MC, Borowiec AM, Jones SC, Zahradka P, Dixon IM. Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. Mol Cell Biochem. 2003;254(1-2):247-56. (Pubitemid 37483760)
67. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002;90(2):128-34. (Pubitemid 34627080)
68. Florholmen G, Aas V, Rustan AC, Lunde PK, Straumann N, Eid H, et al. Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes. J Mol Cell Cardiol. 2004;37(6):1183-93. (Pubitemid 39575163)
69. El-Adawi H, Deng L, Tramontano A, Smith S, Mascareno E, Ganguly K, et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res. 2003;57(1):129-38. (Pubitemid 36009444)
70. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 1995;92(11):4862-6.
71. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122(2):145-55.
72. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-88.
73. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22.
74. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol. 2010;185(9):5512-21.
75. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15(12):1350-62.
76. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124(21):e540-3.
77. Ather S, ChanW, Bozkurt B,Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998-1005.
78. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2013 Sep 5 [Epub ahead of print].
79. .• Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. This paper proposes a new paradigm where the cardiovascular abnormalities in HFpEF can be understood as the downstream consequence of inflammation, including IL-6, associated with comorbid medical illness.
80. Zuliani G, Galvani M, Maggio M, Volpato S, Bandinelli S, Corsi AM, et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis. 2010;213(1):319-24.
81. Inta I,Weber D, Grundt C, Veltkamp R,Winteroll S, Auffarth GU, et al. Correlation of soluble gp130 serum concentrations with arterial blood pressure. J Hypertens. 2009;27(3):527-34.
82. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55(19):2129-37.
83. Peters M, Odenthal M, Schirmacher P, Blessing M, Fattori E, Ciliberto G, et al. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. J Immunol. 1997;159(3):1474-81. (Pubitemid 127484128)
84. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43-58. (Pubitemid 32061655)
85. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol. 2004;173(9):5343-8. (Pubitemid 39392116)
86. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90(6-7):484-94.
87. .• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375-83. This review brings an updated view on the IL-6 blockade in inflammatory diseases and discusses the importance of IL-6 trans-signaling responses.
88. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smoothmuscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999;163(8):4583-9. (Pubitemid 29474529)
89. Migita K, Abiru S,Maeda Y, DaikokuM, Ohata K, NakamuraM, et al. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum Immunol. 2006;67(1-2):27-32.
90. Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, et al. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol. 2006;143(1):125-31.
91. Kovacs E. The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy Biomed Pharmacother. 2005;59(9):498-500. (Pubitemid 41642948)
92. Robak T, Wierzbowska A, Blasinska-Morawiec M, Korycka A, Blonski JZ. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.Mediators Inflamm. 1999;8(6):277-86. (Pubitemid 30232873)
93. Nagaoka T, Sato S, HasegawaM, IhnH, TakeharaK. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol. 2000;27(8):1917-21. (Pubitemid 30670486)
94. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, de Caterina M, Leosco D, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J. 2000;140(6):E28.
95. Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013;6(1):91-8.
96. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26. (Pubitemid 44650950)
97. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005;5(5):683-90. (Pubitemid 40780551)
98. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72(4):482-92.
99. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-95.
100. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol. 2005;28(3):221-30.
101. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720-9.
102. .•• Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822): 1214-24. This pivotal paper co-contributed the first causal link between IL-6 signaling and CV disease. Through singlenucleotide polymorphism (SNP) analyses of the IL6R gene in 133,000 individuals, an IL6R variant (Asp358Ala) was found to protect against coronary artery disease, with effects on circulating IL-6, CRP and fibrinogen concentrations similar to that of tocilizumab in clinical trials.
103. .•• IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822): 1205-13. This pivotal paper co-contributed the first causal link between IL-6 signaling and CV disease. An IL6R variant (Asp358Ala) was associated with increased circulating IL6R and IL6, and reduced CRP and fibrinogen in 125,000 participants. For every copy of 358Ala, the inherited the risk of coronary heart disease was reduced by 3.4%.
104. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731-40. (Pubitemid 41116745)
105. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v38-47.
106. Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, et al. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci USA. 2008;105(38):14692-7.
107. Yamamoto K, Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther. 2012;91(4):574-6.
108. .• Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2011;32(2):281-90. This elegant experimental study demonstrated that inhibition of IL6 trans-signaling with an sgp130Fc fusion protein can dramatically reduce, and even reverse, atherosclerosis in mice. Importantly, sgp130FC did not increase serum lipid levels, a common occurrence with tocilizumab treatment.